Comment on: “Chronic pruritus of unknown origin (CPUO): Uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment” - 18/11/21
Doi : 10.1016/j.jaad.2019.07.081
Sagar P. Patel, BA, BS a, Raveena Khanna, BA a, b, Shawn G. Kwatra, MD a, c, ⁎ 
a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Creighton University School of Medicine, Omaha, Nebraska
c Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
∗Correspondence to: Shawn G. Kwatra, MD, Cancer Research Building II, Johns Hopkins University School of Medicine, Ste 206, 1550 Orleans St, Baltimore, MD 21231Cancer Research Building IIJohns Hopkins University School of MedicineSte 206, 1550 Orleans StBaltimoreMD21231
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr. Kwatra is on the advisory board and serves as a consultant for Menlo Therapeutics, has received grant funding from Kiniksa Pharmaceuticals, and is also a recipient of a Dermatology Foundation Medical Dermatology Career Development Award. Authors Patel and Khanna have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 85 - N° 6
P. e381-e382 - décembre 2021 Retour au numéro
Article précédent
- Reply to: “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”
- Alexander Egeberg, Lars Erik Bryld, Lone Skov
- Reply to “Comment on: Chronic pruritus of unknown origin (CPUO): Uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment”
- Brian S. Kim, Timothy G. Berger, Gil Yosipovitch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?